An apheresis machine separatesthe blood components from the blood directed to the machine from thepatient/donor's veins through tubing. Apheresis can be used for the treatmentof various diseases such as familial hypercholesterolemia, Goodpasture'ssyndrome, hyperviscosity syndrome, myasthenia gravis, the HELLP syndrome ofpregnancy, Waldenstrom's macroglobulinemia, clogging of blood vessels(leukostasis) cause by severely elevated white blood count in leukemia, andseverely elevated platelet counts in leukemia or myeloproliferative disorders.
The global ApheresisEquipment Market is estimated to account for US$ 2,866.4 Mn in terms ofvalue in 2020 and is expected to reach US$ 6,081.8 Mn by the end of 2027.
Global Apheresis EquipmentMarket: Drivers
Increasing prevalence of COVID-19is expected to propel growth of the global apheresis equipment market over theforecast period. For instance, according to a statement by World ApheresisAssociation in April 2020, apheresis therapy can be widely beneficial in thetreatment of patients with the novel coronavirus.
Global Apheresis EquipmentMarket: Opportunities
Lipoprotein apheresis iseffective in the treatment of homozygous familial hypercholesterolemia.However, the therapy is expensive and available in only a few countries.Therefore, reduction in the cost of lipoprotein apheresis and widespreadavailability of the therapy is expected to offer lucrative growth opportunitiesfor the market players.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/517
Global Apheresis EquipmentMarket: Restraints
Lack of trained professionals,especially in emerging economies is expected to limit growth of the market.Hiring skilled staff for both therapeutic and donor apheresis is a majorchallenge faced in both developed and emerging markets. The staff required forapheresis comprises of a practicing doctor and a specialized nurse. Apheresisprocedures are often termed to be labor intensive since they require the staffto be present and vigilant during the entire procedure. The skill requirementcriteria in the practice of apheresis are also different compared to conventionaltherapeutic areas.
Key Takeaways:
Plasmapheresis segment was valuedat US$ 1,303.7 Mn in 2019 and is forecast to reach a value of US$ 2,735.9 Mn by2027 at a CAGR of 9.7% between 2020 and 2027. Frequent and increasing use ofplasmapheresis is expected to support growth of the segment over the forecastperiod.
Neurological disorders segmentheld dominant position in the global apheresis equipment market in 2019,accounting for 52.6% share in terms of value, followed by hematologicaldisorders and renal disorders, respectively. Increasing prevalence of neurologicaldisorders is expected to support growth of the segment over the forecastperiod.
Market Trends
Increasing clinical trials forcystinosis, a rare genetic, metabolic, lysosomal storage disease caused bymutations in the CTNS gene on chromosome 17p13, is expected to boost adoptionof apheresis, thereby boosting growth of the market. For instance, in March2020, AVROBIO, Inc., a clinical-stage gene therapy company, announced that asecond patient in the AVR-RD-04 Phase 1/2 clinical trial in cystinosis has beenenrolled and has completed apheresis.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/apheresis-market-517
However, several pharmaceuticalcompanies have suspended screening, enrollment and apheresis in clinicalstudies. For instance, in March 2020, Bristol-Myers Squibb disclosed that thecompany has temporarily suspended screening, enrollment and apheresis in itscellular therapy clinical studies.
Global Apheresis Equipment Market:Competitive Landscape
Major players operating in theglobal apheresis equipment market include, Asahi Kasei Medical Co., Ltd., TerumoBCT, Inc., Fenwal, Inc., Haemonetics Corp., Therakos, Inc., B. Braun MelsungenAG, and HemaCare Corporation.
Global Apheresis EquipmentMarket: Key Developments
April 2019: Asahi KaseiBioprocess America, a subsidiary of Asahi Kasei Medical Co., Ltd. startedMassachusetts Training Center, for customer training and product collaborationsin virus filtration, bioprocess and fluid management
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/517
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
